Our Pancreas and Biliary Tumor Specialists

New Patient Appointments


Our Specialists: Pioneering New Paths to Treatment

Pancreatic and biliary cancers are challenging diseases. At the Pancreas and Biliary Tumor Center, our specialists are making breakthrough discoveries in every discipline:

  • Our medical oncologists are improving the use of chemotherapy and targeted agents through clinical trials and new treatment approaches, such as with therapies that harness the immune system to fight the cancer.
  • Our surgeons offer the full range of advanced pancreatic surgery, and are pioneering the newest surgical approaches, including laparoscopic and robotic surgeries, and operations to remove larger tumors that more intimately involve surrounding blood vessels.
  • Our radiologists are pioneering the use of imaging tests to allow optimal diagnosis and treatment of patients with pancreaticobiliary tumors or cysts.
  • Our gastroenterologists are identifying new ways to distinguish benign cysts from early cancers and devising new ways to screen for pancreatic cancer in high-risk families.
  • Our pathologists work closely with surgeons and endoscopists to evaluate tissue samples in real-time, leading to faster, more accurate diagnoses.
  • Our radiation oncologists are discovering better combinations of radiation and systemic therapies, including newer targeted agents. They are pioneering stereotactic radiation therapy to treat localized tumors with less damage to surrounding tissues.
  • Our endoscopists are using innovative advanced endoscopic techniques to evaluate tumors and to relieve obstructions through placement of biliary stents.
  • Our scientists are working to understand the fundamental biology of these cancers to identify new ways to prevent and treat these diseases in our patients.

Meet Our Leaders


Thomas E. Clancy, MD, is a surgical oncologist specializing in pancreaticobiliary and liver surgery at Brigham and Women's Hospital and Dana-Farber Cancer Institute, and is Co-Director of the Pancreas and Biliary Tumor Center. He obtained his medical degree from Harvard Medical School, followed by both general surgical residency and surgical oncology fellowships at Brigham and Women's Hospital.

Dr. Clancy's clinical focus is the treatment of gastrointestinal malignancies, specifically pancreatic, biliary, and liver tumors. A high-volume clinical surgical oncologist, Dr. Clancy has been a leader in the development and adoption of minimally invasive techniques including robotic pancreatectomy, and is the surgical director of the BWH Interdisciplinary Pancreatic Cystic Tumor (IMPACT) clinic focusing on collaborative multidisciplinary management of patients with cystic pancreatic neoplasms. In addition, he is the director of the BWH program in Total Pancreatectomy with Islet Cell Autotransplantation for management of patients with refractory chronic pancreatitis.


Joseph Mancias, MD, PhD, is a radiation oncologist in the Gastrointestinal Oncology disease center of Dana-Farber Brigham Cancer Center. Dr. Mancias specializes in the care of patients with gastrointestinal cancers and runs an independent laboratory at Dana-Farber Cancer Institute that focuses on the biology of pancreatic cancer.

Dr. Mancias received his medical and graduate degrees as part of the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, earning a PhD degree from the Weill Cornell Graduate School of Medical Sciences and an MD from Weill Cornell Medical College. He completed an internship in Internal Medicine at Brigham and Women’s Hospital, followed by a residency in Radiation Oncology in the Harvard Radiation Oncology Program (HROP). He subsequently completed a research fellowship in Pancreatic Cancer Biology at Harvard Medical School and Dana-Farber Cancer Institute.


Harshabad (Harsh) Singh, MBBS, is a medical oncologist who specializes in the treatment of gastrointestinal tract cancers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, and is Co-Director of the Pancreas and Biliary Tumor Center. He received his medical doctorate, first in his class, from the Government Medical College and Hospital in Chandigarh, India.

Dr. Singh completed his internal medicine residency and chief residency at Massachusetts General Hospital and fellowship in medical oncology at Dana-Farber Cancer Institute. Subsequently, he pursued postdoctoral training in cancer epigenetics in the laboratory of Ramesh Shivdasani, MD, PhD, at Dana-Farber. Dr. Singh is a translational researcher who is focused on using his basic science training and expertise to bring novel therapies from the bench to the clinic for his patients.


Brian M. Wolpin, MD, MPH, is a medical oncologist and translational cancer researcher at Dana-Farber Cancer Institute and Harvard Medical School, and is Co-Director of the Pancreas and Biliary Tumor Center. Dr. Wolpin obtained his medical degree from Harvard Medical School and Master of Public Health Degree from Harvard School of Public Health. He completed a residency in internal medicine at Brigham and Women's Hospital and a medical oncology fellowship at Dana-Farber Cancer Institute.

Dr. Wolpin's clinical practice involves the medical oncology care of patients with gastrointestinal cancers, with a focus on pancreatic and biliary cancer. He is dedicated to the quality of life of his patients, while assisting them in finding the most effective and tolerable therapies to treat their cancer. He has published articles and run multiple clinical trials testing new therapies for patients with pancreatic cancer, including therapies identified by researchers at Dana-Farber Brigham Cancer Center. He also leads a translational research program dedicated to understanding new approaches to the early diagnosis and treatment of pancreatic cancer.

See the complete list of our gastrointestinal cancer specialists.